Should I Buy BMRA? BMRA 2026 Analysis

Should You Buy Biomerica Inc (BMRA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

2.390

1 Day change

-1.40%

52 Week Range

8.800

Analysis Updated At

2026/01/28

BMRA is not a good buy right now for a Beginner, long-term investor with $50k–$100k who is impatient. The technical trend is bearish, near-term pattern odds lean negative, there are no proprietary buy signals today, and the latest quarter (2026/Q2) shows falling revenue and a sharply weaker gross margin. Best stance: HOLD/AVOID new buying at current levels.

Technical Analysis

Trend/structure: Bearish. Moving averages are stacked bearishly (SMA_200 > SMA_20 > SMA_5), indicating sustained downside momentum. Momentum: MACD histogram is -0.0321 and negatively expanding, confirming bearish momentum is strengthening. RSI: RSI_6 at ~32.7 is weak and near oversold territory, which can support a short-lived bounce, but it is not a reversal signal by itself. Key levels: Current price 2.41 is essentially sitting on S1 (2.414). A clean break below risks a move toward S2 (2.316). Upside resistance starts near Pivot 2.572 then R1 2.73. Stat/pattern outlook: Similar-candlestick analog suggests ~60% chance of -2.32% next day, -1.74% next week, -0.37% next month, reinforcing a weak near-term bias. Intellectia Proprietary Trading Signals - [AI Stock Picker](module://ai_stock_pick): No signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock today.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Options activity/sentiment: Put-call ratios read as 0.0 largely because the provided open interest/volume fields are blank, suggesting limited/illiquid options data rather than a strong directional consensus. Volatility: Historical volatility is very high (~73.23), which implies the stock price can move sharply; this typically aligns with higher risk and less stable long-term entries. Takeaway: Options data here does not provide a reliable bullish sentiment read; it’s more indicative of limited actionable options flow.

Technical Summary

Sell

Buy

Positive Catalysts

No news in the recent week (no positive event-driven catalyst identified).
Potential technical positive: RSI near oversold could allow a short-term dead-cat bounce if S1 holds.
Positioning: Hedge fund and insider activity described as Neutral (no recent negative signal from flows, but also no confidence-boosting buying trend).

Neutral/Negative Catalysts

Pattern-based projection skews to modest declines over day/week/month.

Financial Performance

Latest quarter provided: 2026/Q2. Revenue: 1.21M, down -26.04% YoY (clear top-line contraction). Net income: -1.32M, improved 38.95% YoY but still a sizable loss (losses narrowing, not profitability). EPS: -0.45, improved 2.27% YoY (minor improvement, still negative). Gross margin: 4.21, down -84.24% YoY (major deterioration and the biggest red flag; indicates weaker unit economics/pricing/power or cost pressure). Overall: The quarter shows improving losses but worsening operating quality (margin) and shrinking revenue—not the growth profile a beginner long-term investor should buy aggressively today.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analyst rating/price target trend: Not provided in the data, so no confirmed recent upgrades/downgrades or target changes can be summarized. Wall Street pros/cons view (based on available info only): Pros—losses improved YoY and no notable insider/hedge fund selling trend reported. Cons—revenue decline, gross margin collapse, and bearish technical setup with no proprietary buy signals today.

Analyst Rating

Wall Street analysts forecast BMRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BMRA is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy